BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Metabolic dysregulation has been implicated in major depressive disorder (MDD), but the causal relationship between plasma ...

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

US clinical-stage biopharma Biohaven has reported disappointing results from a Phase II proof-of-concept study evaluating BHV ...

Depression, one of the most prevalent mental health disorders worldwide, is characterized by persistent feelings of sadness, ...